Podcasts & RSS Feeds
Most Active Stories
- Here's What The Big I-90 Closure Will Look Like. How Will You Survive?
- Study Finds MRSA 'Superbug' Lurking At Washington Firehouses
- 5 Reasons Eating Bugs Could Save The World, According To Seattle's Own 'Bug Chef'
- When A Bomb Goes Off During Your Study On Trauma: New UW Findings On PTSD
- Report Shows Coal, Oil Trains Would Quadruple Rail Traffic, Alarming Lawmakers
News & Music Contributors
Shots - Health News
Tue February 4, 2014
Drugmakers And NIH Band Together To Speed Up Research
Originally published on Tue February 4, 2014 12:30 pm
The National Institutes of Health is teaming up with major drug companies in a new effort to identify disease-related molecules and biological processes that could lead to future medicines.
The public-private partnership is called AMP, for the "Accelerating Medicines Partnership," and it will focus first on Alzheimer's disease, Type 2 diabetes, and two autoimmune disorders: rheumatoid arthritis and lupus.
This is a five-year, $230 million venture. NIH is splitting the cost with industry. In addition to ten companies that include Pfizer, Merck, and Johnson & Johnson, nonprofits like the American Diabetes Association and the Alzheimer's Association have also joined.
They'll work together to identify the most promising biological targets for new therapies. All the scientific data produced by the venture will be shared publicly. "Even if we weren't working with companies we would do this," says Dr. Francis Collins, director of the NIH. He officially unveiled the partnership at a press event in Washington, D.C., and in a blog post. The Wall Street Journal reported on the venture late Monday.
Collins says after new targets are found, companies can then develop drugs that take advantage of them. The goal is to speed new therapies to market, while avoiding the costly and disappointing failures that currently plague the drug-development process.
What sets this venture apart is its comprehensive approach in prioritizing diseases where the science is evolving and patients' needs are pressing, plus the breadth of this many companies and the NIH working together, says Mikael Dolsten, head of research and development at Pfizer.
"I have considerable enthusiasm that this is unique," says Dolsten. "It's complementary, and we should aspire high here."
Hopefully, the collaboration will help illuminate the fundamental basis of what's driving disease, says Lisa Olson, vice president of immunology research at AbbVie Bioresearch Center, Inc., one of the industry partners. Asked if she had seen a partnership similar to this one before, she said simply, "No."